The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new menopause therapy Veozah ...

Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Metastatic ... HER2 expressing non-small cell lung cancer, non-muscle invasive bladder cancer (NMIBC), penile ...

Pfizer also has high hopes for PD-1/PD-L1 inhibitor sasanlimab for non-muscle invasive bladder cancer in the CREST study, and CD3xBCMA bispecific Elrexfio (elranatamab) in MagnetisMM-5 as a ...

Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...

Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a ...

The Pfizer Foundation has provided $15 million investment to a three-year initiative to improve the lives of women with breast cancer in Rwanda, Ghana, and Tanzania. The Grant funding will be provided ...

Pfizer Inc. (NYSE:PFE) will increase its dividend from last year's comparable payment on the 7th of March to $0.43. This will take the annual payment to 6.5% of the stock price, which is above ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...